Last reviewed · How we verify

Mundipharma Manufacturing Pte Ltd. — Portfolio Competitive Intelligence Brief

Mundipharma Manufacturing Pte Ltd. pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
7.5% Povidone-Iodine [PVP-I] 7.5% Povidone-Iodine [PVP-I] marketed
Normal saline gargle Normal saline gargle marketed Saline rinse / Oral hygiene agent Otolaryngology / Oral Care
Plain non antibacterial soap Plain non antibacterial soap marketed Hygiene/Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Mundipharma Manufacturing Pte Ltd.:

Cite this brief

Drug Landscape (2026). Mundipharma Manufacturing Pte Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mundipharma-manufacturing-pte-ltd. Accessed 2026-05-17.

Related